Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15129MR)

This product GTTS-WQ15129MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15129MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14727MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ10024MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ2169MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ4783MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ1362MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ9520MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ9681MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ5372MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW